Most read articles by the same author(s)
- Paola Raimondo, Giorgio Casilli, Martina Isernia, Dario Lidonnici, Roberto Ravasio, Virginia Ronco, Elena Lanati, The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020 , Global and Regional Health Technology Assessment: Vol. 7 No. 1 (2020): January-December 2020
- Gian Domenico Sebastiani, Marta Mosca, Roberto Ravasio, Pietro Brambilla, Paola Raimondo, Andrea Doria, Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis , Global and Regional Health Technology Assessment: Vol. 9 No. 1 (2022): January-December 2022
- Costantino Di Carlo, Antonio Maiorana, Ignazia Poidomani, Roberto Ravasio, Adriano Vercellone, Clinical and Economic Management of Uterine Fibroids: The Point of View of a Decision Makers Board , Global and Regional Health Technology Assessment: Vol. 3 No. 3 (2016): September-December 2016
- Roberto Ravasio, Silvia Antonelli, Veronica Rogai, Walid Fakhouri, Jean Philippe Capron, Serena Losi, Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy , Global and Regional Health Technology Assessment: Vol. 5 No. 1 (2018): January-December 2018
- Roberto Ravasio, Cost-Effectiveness Analysis of Long-Acting Bronchodilators for the Treatment of COPD (Moderate to Very Severe) , Global and Regional Health Technology Assessment: Vol. 2 No. 3 (2015): September-December 2015
- Roberto Ravasio, Giuseppe Nicolò, Marco Vaggi, Cost-effectiveness analysis of paliperidone palmitate versus long-acting risperidone as maintenance treatment in schizophrenia patients in Italy , Global and Regional Health Technology Assessment: Vol. 2 No. 1 (2015): January-April 2015
- Roberto Ravasio, Giampiero Girolomoni, Roberto Gorla, Budget impact analysis of the etanercept biosimilar: the Italian scenario , Global and Regional Health Technology Assessment: Vol. 5 No. 1 (2018): January-December 2018
- Adolfo Favaretto, Francesco Grossi, Alessandro Morabito, Roberto Ravasio, Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations , Global and Regional Health Technology Assessment: Vol. 4 No. 1 (2017): January-December 2017
- Roberto Ravasio, Giorgio Grassi, The economic impact of the correct insulin injection technique associated with the use of 4 mm 32G needles in the treatment of patients with type 2 diabetes , Global and Regional Health Technology Assessment: Vol. 5 No. 1 (2018): January-December 2018
- Roberto Ravasio, Cost-Effectiveness Analysis of Triptorelin versus Leuprolide in the Treatment of Advanced Prostate Cancer , Global and Regional Health Technology Assessment: Vol. 3 No. 3 (2016): September-December 2016